Skip to content
Boca Raton City Online – Lifestyle
Author:
NewAmsterdam Pharma N.V.
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
November 4, 2026
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
November 3, 2026
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
September 29, 2026
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
September 21, 2026
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 3, 2026
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
September 2, 2026
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
August 26, 2026
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 6, 2026
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 5, 2026
1
2
Next Page
→